Aducanumab (brand name Aduhelm) is the first FDA-approved, pharmacologic treatment for Alzheimer’s disease (AD) but many uncertainties remain regarding both efficacy and safety. Of paramount concern are associated adverse effects including cerebral edema hemorrhage which prompted a post-approval study. Aside from safety concerns, withdrawal market may occur if it fails to demonstrate as describ...

OBJECTIVES To explore the use of a questionnaire to obtain representative public opinions on health services. To examine residents' priorities, knowledge, and views on the public's role in decision making. DESIGN Self administered postal questionnaire. POPULATION Random sample of 1500 residents in Bath District Health Authority, drawn from electoral registers. MAIN OUTCOME MEASURES Levels...

In this issue we present an exchange of views arising from the DSM-IV diagnostic criteria for delusions. Anchoring the discussion is an article by Drs. Mujica-Parodi and Sackeim in which they examine the DSM-IV requirement that to be classified as a delusion, a belief must be discordant with beliefs ordinarily accepted by the patient’s culture or subculture. They propose that an information-pro...